Supplementary Information

Catalyst- and additive-free syntheses of rhodanine and S-alkyl dithiocarbamate derivatives from sulfoxonium ylides

Ajay Sharma and Satyendra Kumar Pandey*

Department of Chemistry, Institute of Science, Banaras Hindu University, Varanasi, 221005, India

*Corresponding Author: Telephone number: +91-700-934-6528

E-mail address: skpandey.chem@bhu.ac.in

Table of contents

1.	General information	S1
2.	Table S1	S2
3	Table S2	S3
4.	Structures of α -ester sulfoxonium ylides	S3
5.	General procedure for preparation of α -ester sulfoxonium ylides 1a-1i	S4
6.	Procedure for preparation of α -ester sulfoxonium ylides 1j	S4
7.	General procedure for the synthesis of compounds, 4	S5
8.	Characterization of Compounds, 4	S5-S7
9.	General procedure for the synthesis of compounds, 6	S7
10.	Characterization of Compounds, 6	S7-S12
11.	Unsuccessful examples of primary amines	S12
12.	General procedure for synthesis of compounds, 8	S12
13.	Characterization of Compounds, 8	S12-S16
14.	Unsuccessful examples of secondary amines	S16
15.	Synthesis of FE15	S16-S17
16.	Characterization of intermediate, IIa	S17
17.	References	S17-S18
18.	¹ H and ¹³ C NMR Spectra of Compounds 4, 6, 8, 9 and Ha	S19-S70

1. General information: All the chemicals and solvents were used as received without further purification. Organic extracts were dried over anhydrous Na₂SO₄. Progress of the reactions was monitored by TLC using precoated aluminium plates of Merck Kieselgel 60 F254. Column chromatography was performed on silica gel (100-200 mesh) using a mixture of n-hexane/ethyl acetate. ¹H and ¹³C NMR spectra were recorded in CDCl₃ (unless otherwise mentioned) on JEOL ECS and Brucker operating at 500/126 and 600/151 MHz, respectively. Chemical shifts are reported in δ (ppm), referenced to TMS and were reported as s (singlet), d (doublet), t (triplet), q (quadruple), dd (doublet of doublet), m (multiplet) etc. The coupling constants *J*, are reported in Hertz (Hz). Mass spectra were recorded on SCIEX X500R QTOF (TOF-MS).

2. Table S1. Synthesis of rhodanines: Optimization^{*a*}

		+ CS ₂ + an so 2 ;	nine <u>Solve</u> urce - DMS 3		s NH O a
entry	amines	solvent	temp	time	yield ^b of 4a
			(°C)	(h)	(%)
1^c	NH ₃ .H ₂ O	MeCN	rt	4	43
2^c	NH ₃ .H ₂ O	DMF	rt	4	36
3 ^c	NH ₃ .H ₂ O	DMSO	rt	4	27
4 ^c	NH ₃ .H ₂ O	Toluene	rt	4	38
5 ^c	NH ₃ .H ₂ O	CH_2Cl_2	rt	4	32
6 ^{<i>c</i>}	NH ₃ .H ₂ O	THF	rt	4	62
7^c	NH ₃ .H ₂ O	H ₂ O	rt	12	0
8 ^c	NH ₃ .H ₂ O	H ₂ O	100	12	0
9 ^c	NH ₃ .H ₂ O	MeOH	rt	4	58
10^d	NH ₃ .MeOH	MeOH	rt	2	89
11	NH ₄ Cl	MeOH	rt	12	NR
12	HCOONH ₄	MeOH	rt	5	30
13	CH ₃ COONH ₄	MeOH	rt	4	61
14	CH ₃ COONH ₄	THF	rt	4	55
15	$(NH_4)_2SO_4$	MeOH	rt	12	0

^{*a*}General conditions: Except where otherwise noted, all reactions were conducted using 1a (0.50 mmol), 2 (1.0 mmol), and amine 3 (0.75 mmol) in 3 mL of solvent at given temp. in a sealed tube.

^bIsolated yield.

 $^c\!25\%$ aq. NH_3 (0.50 mL, 0.75 mmol) was used.

 $^{d}2.0~M~NH_{3.}MeOH~(0.40~mL,~0.75~mmol)~$ was used.

3. Table S2. Synthesis of intermediate IIa: Optimization^a

O S					ş	NHBn S	s S
		+ CS ₂ +	H ₂ N	Solvent		+	<i>Y</i> ¹
	1a	2	5a		lla	6a	

entry	solvent	temp (°C)	time (h)	yield ^b of IIa (%)	yield ^b of 6a (%)
1	MeOH	rt	1.5 h	N.D. ^c	92
2	MeOH	0 °C	5 h	12	68
3 ^f	MeOH	-10 °C	12 h	Trace	Trace
4 ^f	MeOH	-20 °C	12 h	$N.R.^d$	N.R.
5 ^f	THF	0 °C	4 h	Trace	47
6 ^f	Toluene	0 °C	5 h	18	42
7 ^f	Toluene	-5 °C	6 h	24	Trace
8 ^f	DCM	0 °C	4 h	N.D.	N.I. ^e
9 ^f	CHCl ₃	0 °C	4 h	N.D.	N.I.
10	CH ₃ CN	0 °C	4 h	N.D.	N.I.

^{*a*}Except where otherwise noted, all reactions were conducted using **1a** (1.0 mmol), **2** (1.50 mmol), and benzyl amine **5a** (1.20 mmol) in 5 mL of solvent, used new glassware (25 mL round bottom flask) and stir-bar. The reaction mixture was stirred at given temp for given time.

^bIsolated yield.

^cNot detected.

^dNo reaction.

^eNot isolated.

^fSulfoxonium ylide recovered.

4. Structures of α -ester sulfoxonium ylides used in this study:



5. General procedure for preparation of α -ester sulfoxonium ylides 1a-1i:



All the α -ester sulfoxonium ylides were synthesized from α -diazoesters¹ according to the known literature procedure.^{2c} Briefly, to a stirred solution of corresponding α -diazoesters (10.0 mmol, 1 equiv.) in 7 mL DMSO was added 10 mol% copper powder at 50 °C. The reaction mixture was stirred for 24 h at the same temperature. After completion of the reaction, the reaction was cooled to r.t., diluted with EtOAc (20 mL) and the organic phase was washed with ice cold water (3 x 30 mL) until there was no more DMSO in the organic phase (analysis by TLC). The organic phase was dried over anhydrous Na₂SO₄, concentrated under reduced pressure and crude material was purified by crystallization in the minimal amount of hot EtOAc (5-10 mL), followed by slow addition of 20 mL of hexane, which was filtered through a Buchner funnel under vacuum to afford the corresponding α -ester sulfoxonium ylides as solid in the stated yields (**1a-1i**). Spectroscopic data was consistent with previous reports.²

6. Procedure for preparation of α -ester sulfoxonium ylides 1j:



Sulfoxonium ylide **1j** was synthesized according to the known literature procedure.³ Briefly, to a stirred solution of potassium *tert*-butoxide (4.50 g, 40.0 mmol, 3.80 equiv.) in anhydrous THF (20 mL) was added trimethylsulfoxonium iodide (7.40 g, 33.86 mmol, 3.20 equiv.) at room temperature. The resulting solution was heated to reflux for 2 h. Further, the reaction mixture was cooled to 0 °C, followed by dropwise addition of methyl chloroformate (1.0 g, 10.5 mmol, 1.0 equiv.) in THF (15 mL) solvent. The reaction was allowed to bring at room temperature and stirred for additional 3h. After completion of reaction as monitored by TLC, the solvent was evaporated after that water (30 mL) and EtOAc (30 mL) were added to the resulting slurry. The organic layer was separated and the aqueous layer was washed with ethyl acetate (2 x 30 mL). The combined organic layer was dried over anhydrous Na₂SO₄, filtered and evaporated to dryness. The crude product was purified by EtOAc/diethyl ether with constant stirring, resulting in precipitation of pure ylide, which was filtered through a Buchner funnel under vacuum and washed with cold EtOAc/diethylether to afford the corresponding sulfoxonium ylide **1j** (1.20 g, 78%) as solid compound. Spectroscopic data was consistent with previous reports.³

S5

7. General procedure for the synthesis of compounds, 4

To a stirred solution of methanolic NH₃ **3** (0.40 mL, 0.75 mmol, 1.5 equiv., 2.0 M in MeOH) in MeOH (3 mL) in a sealed tube were added CS₂ **2** (1.0 mmol, 2 equiv.) and α -ester sulfoxonium ylide **1** (0.5 mmol, 1 equiv.) at room temperature, and the reaction mixture was stirred for 2 h. After completion of reaction as monitored by TLC, the solvent was evaporated under reduce pressure and extracted with EtOAc (3 x 7 mL). The organic extract was dried over anhydrous Na₂SO₄ and removed solvent under reduced pressure. The crude product **4** was purified by column chromatography (silica gel, 100-200 mesh; ethyl acetate/hexane 1.5/8.5) which afforded the desired products **4** in good to excellent yields.

8. Characterization of Compounds, 4

5-Phenyl-2-thioxothiazolidin-4-one, 4a

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.5/8.5); White solid (93 mg, 89%); mp: 154-156 °C; ¹H NMR (600 MHz, DMSO-d₆) δ : 13.41 (brs, 1H), 7.43 - 7.40 (m, 2H), 7.38 - 7.36 (m, 3H), 5.91 (s, 1H); ¹³C{¹H} NMR (151 MHz, DMSO-d₆) δ : 203.1, 177.3, 134.8, 129.1, 128.7, 128.6, 57.4.; HRMS (ESI⁺) *m/z* C₉H₇NOS₂ [M + H]⁺ calcd. 210.0042, found 210.0043.

2-Thioxo-5-(p-tolyl)thiazolidin-4-one, 4b

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.5/8.5); White solid (100 mg, 90%); mp: 135-137 °C; ¹H NMR (500 MHz, DMSO-d₆) δ : 13.36 (s, 1H), 7.25 (d, *J* = 8.0 Hz, 2H), 7.21 (d, *J* = 8.2 Hz, 2H), 5.87 (s, 1H), 2.30 (s, 3H); ¹³C{¹H} NMR (126 MHz, DMSO-d₆) δ : 203.0, 177.4, 138.2, 121.0, 120 (c, 120 4, 57.1, 20.7, MDMS) (TGI[±]) = (c, MMSO-d₆) δ : 204.0, 177.4, 138.2, 121.0, 120 (c, 120 4, 57.1, 20.7, MDMS) (TGI[±]) = (c, MMSO-d₆) δ : 204.0, 177.4, 138.2, 121.0, 120 (c, 120 4, 57.1, 20.7, MDMS) (TGI[±]) = (c, MMSO-d₆) δ : 204.0, 177.4, 138.2, 121.0, 120 (c, 120 4, 57.1, 20.7, MDMS) (TGI[±]) = (c, MMSO-d₆) δ : 204.0, 177.4, 138.2, 121.0, 120 (c, 120 4, 57.1, 20.7, MDMS) (TGI[±]) = (c, MMSO-d₆) δ : 204.0, 177.4, 138.2, 121.0, 120 (c, 120 4, 57.1, 20.7, MDMS) (TGI[±]) = (c, MMSO-d₆) δ : 204.0, 177.4, 138.2, 121.0, 120 (c, 120 4, 57.1, 20.7, MDMS) (TGI[±]) = (c, 120 4, 57.1, 20.7, M

131.8, 129.6, 128.4, 57.1 20.7.; HRMS (ESI⁺) m/z C₁₀H₉NOS₂ [M + H]⁺ calcd. 224.0199, found 224.0206.

2-Thioxo-5-(o-tolyl)thiazolidin-4-one, 4c

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.5/8.5); White solid (95 mg, 86%); mp: 139-141 °C; ¹H NMR (500 MHz, DMSO-d₆) δ : 13.45 (s, 1H), 7.29 - 7.23 (m, 4H), 6.14 (s, 1H), 2.30 (s, 3H); ¹³C{¹H} NMR (126 MHz, DMSO-d₆) δ : 203.0, 177.4, 137.0, 132.8, 131.0, 129.0, 128.8, 126.7, 55.5, 18.95 (s).; HRMS (ESI⁺) m/z C₁₀H₉NOS₂ [M + H]⁺ calcd. 224.0199, found 224.0205.

5-(4-Methoxyphenyl)-2-thioxothiazolidin-4-one, 4d

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 2.0/8.0); White solid (109 mg, 92%); mp: 109-111 °C;





Ö 4b



¹H NMR (500 MHz, DMSO-d₆) δ : 13.35 (s, 1H), 7.28 (d, J = 8.4 Hz, 2H), 6.96 (d, J = 8.2 Hz, 2H), 5.86 (s, 1H), 3.75 (s, 3H); ¹³C{¹H} NMR (126 MHz, DMSO-d₆) δ : 203.1, 177.5, 159.5, 129.9, 126.5, 114.5, 57.0, 55.2; HRMS (ESI⁺) m/z C₁₀H₉NO₂S₂ [M + H]⁺ calcd. 240.0148, found 240.0161.

5-(3,4-Dimethoxyphenyl)-2-thioxothiazolidin-4-one, 4e

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 2.5/7.5); White solid (122 mg, 91%); mp: 115-118 °C; ¹H NMR (500 MHz, DMSO-d₆) δ : 13.33 (s, 1H), 6.98 - 6.93 (m, 2H), 6.89 - 6.88 (m, 1H), 5.85 (s, 1H), 3.75 (brs, 6H); ¹³C{¹H} NMR (126 MHz, DMSO-d₆) δ :

203.0, 177.3, 149.1, 148.9, 126.6, 121.0, 112.1, 112.0 57.3, 55.6, 556.5; HRMS (ESI⁺) *m/z* C₁₁H₁₁NO₃S₂ [M + H]⁺ calcd. 270.0253, found 270.0248.

5-(4-Chlorophenyl)-2-thioxothiazolidin-4-one, 4f

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.5/8.5); White solid (103 mg, 85%); mp: 130-132 °C; ¹H NMR (500 MHz, DMSO-d₆) δ : 13.43 (s, 1H), 7.48 (d, *J* = 8.0 Hz, 2H), 7.42 (d, *J* = 9.1 Hz, 2H), 5.95 (s, 1H); ¹³C{¹H} NMR (126 MHz, DMSO-d₆) δ : 203.4, 177.6,

134.3, 133.9, 131.0, 129.6, 57.1.; HRMS (ESI⁺) m/z C₉H₆ClNOS₂ [M + H]⁺ calcd. 243.9652, found 243.9661.

5-(3-Chlorophenyl)-2-thioxothiazolidin-4-one, 4g

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.5/8.5); White solid (100 mg, 83%); mp: 132-135 °C; ¹H NMR (500 MHz, DMSO-d₆): δ 13.44 (s, 1H), 7.48 (s, 1H), 7.45 (d, *J* = 4.9 Hz, 2H), 7.36 - 7.35 (m, 1H), 5.94 (s, 1H); ¹³C{¹H} NMR (126 MHz, DMSO-d₆) δ :

202.8, 176.8, 137.0, 133.5, 131.0, 128.7, 128.6, 127.2, 56.7.; HRMS (ESI⁺) *m/z* C₉H₆ClNOS₂ [M + H]⁺ calcd. 243.9652, found 243.9655.

5-Benzyl-2-thioxothiazolidin-4-one, 4i⁴

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.5/8.5); White solid (90 mg, 81%); mp: 120-122 °C; ¹H NMR (500 MHz, DMSO-d₆) δ : 13.17 (brs, 1H), 7.33 - 7.30 (m, 2H), 7.26 - 7.23 (m, 3H), 5.03 (dd, J = 9.2, 4.1 Hz, 1H), 3.37 (dd, J = 14.1, 4.7 Hz, 1H), 3.17 (dd,

 $J = 14.0, 8.9 \text{ Hz}, 1\text{H}; {}^{13}\text{C}\{{}^{1}\text{H}\} \text{ NMR} (126 \text{ MHz}, \text{DMSO-d}_{6}) \delta: 203.3, 178.0, 136.6, 129.1, 128.5, 127.1, 55.7, 36.5.; \text{HRMS} (\text{ESI}^{+}) m/z \text{ C}_{10}\text{H}_{9}\text{NOS}_{2} [\text{M} + \text{H}]^{+} \text{ calcd. } 224.0199, \text{ found } 224.0204.$



CI

4f





4i

2-Thioxothiazolidin-4-one, 4j⁵

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 2.5/7.5); Red solid (51mg, 78%); mp: 145-147 °C; ¹H NMR (600 MHz, DMSO-d₆) δ : 13.13 (s, 1H), 4.26 (s, 2H); ¹³C{¹H} NMR (126 MHz, DMSO-d₆) δ : 205.3, 176.7, 39.2.



To a stirred solution of CS₂ **2** (0.75 mmol, 1.50 equiv.) in MeOH (3 mL) were added corresponding 1° amines **5** (0.6 mmol, 1.2 equiv.) and α -ester sulfoxonium ylide **1** (0.5 mmol, 1.0 equiv.) at room temperature, and the reaction mixture was stirred for 1.5 h. After completion of reaction as monitored by TLC, the solvent was evaporated under reduce pressure and extracted with EtOAc (3 x 10 mL). The organic extract was dried over anhydrous Na₂SO₄ and removed solvent under reduced pressure. The crude product **6** was purified by column chromatography (silica gel, 100-200 mesh; ethyl acetate/hexane 1.0/9.0) which afforded the desired products in good to excellent yields.

10. Characterization of Compounds, 6

3-Benzyl-5-phenyl-2-thioxothiazolidin-4-one, 6a⁶

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.0/9.0); White solid (139 mg, 93%); mp: 88-90 °C; ¹H NMR (500 MHz, CDCl₃) δ : 7.44 - 7.39 (m, 2H), 7.36 - 7.35 (m, 3H), 7.33 - 7.26 (m, 5H), 5.28 - 5.25 (m, 2H), 5.18 - 5.15 (m, 1H); ¹³C{¹H}NMR (126 MHz, CDCl₃) δ : 7.44 - 7.39 (m, 2H), 7.36 - 7.35 (m, 2H), 7.33 - 7.26 (m, 5H), 5.28 - 5.25 (m, 2H), 5.18 - 5.15 (m, 1H); ¹³C{¹H}NMR (126 MHz, CDCl₃) δ : 7.44 - 7.39 (m, 2H), 7.36 - 7.35 (m, 2H), 7.33 - 7.26 (m, 5H), 5.28 - 5.25 (m, 2H), 5.18 - 5.15 (m, 1H); ¹³C{¹H}NMR (126 MHz, CDCl₃) δ : 7.44 - 7.39 (m, 2H), 7.36 - 7.35 (m, 2H), 7.36 - 7.35 (m, 2H), 7.38 - 7.26 (m, 5H), 5.28 - 5.25 (m, 2H), 5.18 - 5.15 (m, 1H); ¹³C{¹H}NMR (126 MHz, CDCl₃) δ : 7.44 - 7.39 (m, 2H), 7.36 - 7.35 (m, 2H), 7.38 - 7.26 (m, 5H), 5.28 - 5.25 (m, 2H), 5.18 - 5.15 (m, 1H); ¹³C{¹H}NR (126 MHz, CDCl₃) δ : 7.44 - 7.39 (m, 2H), 7.36 - 7.35 (m, 2H), 7.36 - 7.35 (m, 2H), 7.38 - 7.26 (m, 5H), 5.28 - 5.25 (m, 2H), 5.18 - 5.15 (m, 1H); ¹³C{¹H}NR (126 MHz, CDCl₃) δ : 7.44 - 7.39 (m, 2H), 7.36 - 7.35 (m, 2H), 7.38 - 7.26 (m, 2H), 7.38 - 7.28 (m, 2H), 7.38 - 7.28 (m, 2H), 7.38 (m, 2H), 7.38 (m, 2



3-Benzyl-2-thioxo-5-(p-tolyl)thiazolidin-4-one, 6b

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.0/9.0); White solid (140 mg, 90%); mp: 95-98 °C; ¹H NMR (500 MHz, CDCl₃) δ : 7.41 (d, *J* = 6.1 Hz, 2H), 7.32 - 7.27 (m, 3H), 7.16 (s, 4H), 5.26 (d, *J* = 13.9 Hz, 1H), 5.22 (s, 1H), 5.17 (d, *J* = 13.9 Hz,

S N O 6b

1H), 2.34 (s, 3H): ¹³C{¹H} NMR (126 MHz, CDCl₃) δ : 200.1, 175.3, 139.4, 135.0, 130.9, 130.1, 129.0, 128.7, 128.3, 54.3, 48.0, 21.3.; HRMS (ESI⁺) *m/z* C₁₇H₁₅NOS₂ [M + H]⁺ calcd. 314.0668, found 314.0671.

3-Benzyl-2-thioxo-5-(o-tolyl)thiazolidin-4-one, 6cPurified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.0/9.0); White solid (142 mg, 91%); mp: 109-112 °C; ¹H NMR (500 MHz, CDCl₃) δ : 7.45 (d, J = 7.4 Hz, 2H), 7.32 - 7.27 (m, 3H), 7.22 (t, J = 7.3 Hz, 1H), 7.18 -



7.13 (m, 2H), 7.10 (d, J = 7.7 Hz, 1H), 5.48 (s, 1H), 5.27 - 5.20 (m, 2H), 2.27 (s, 3H); ¹³C{¹H} NMR





 $(126 \text{ MHz}, \text{CDCl}_3)$ δ : 200.0, 175.2, 137.0, 134.8, 132.3, 131.4, 129.27, 129.20, 128.7, 128.6, 128.3, 127.0, 52.0, 48.0, 19.6.; HRMS (ESI⁺) *m/z* C₁₇H₁₅NOS₂ [M + H]⁺ calcd. 314.0668, found 314.0676.

3-Benzyl-5-(4-methoxyphenyl)-2-thioxothiazolidin-4-one, 6d

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.5/8.5); White solid (151 mg, 92%); mp: 110-113 °C; ¹H NMR (500 MHz, CDCl₃) δ : 7.41 (d, *J* = 8.0 Hz, 2H), 7.30 - 7.27 (m, 3H), 7.19 (d, *J* = 8.3 Hz, 2H), 6.87 (d, *J* = 8.5 Hz, 2H), 5.26 (d, *J* =

13.8 Hz, 1H), 5.21 (s, 1H), 5.16 (d, J = 14.2 Hz, 1H), 3.78 (s, 3H); ¹³C {¹H} NMR (151 MHz, CDCl₃) δ : 195.3, 170.6, 155.5, 130.2, 124.8, 124.2, 123.9, 123.5, 120.8, 110.0, 50.7, 49.3, 43.2; HRMS (ESI⁺) $m/z C_{17}H_{15}NO_2S_2 [M + H]^+$ calcd. 330.0617, found 330.0627.

3-Benzyl-5-(4-chlorophenyl)-2-thioxothiazolidin-4-one, 6e

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.0/9.0); Colorless oil (144 mg, 87%); ¹H NMR (500 MHz, CDCl₃) δ : 7.41 - 7.39 (m, 2H), 7.35 - 7.29 (m, 5H), 7.24 - 7.22 (m, 2H), 5.26 (d, *J* = 14.1 Hz, 1H), 5.24 (s, 1H), 5.17 (d, *J* = 14.5 Hz, 1H);

¹³C{¹H} NMR (126 MHz, CDCl₃) δ : 199.3, 174.8, 135.5, 134.8, 132.4, 129.7, 129.8, 129.0, 128.8, 128.4, 53.8, 48.1.; HRMS (ESI⁺) *m/z* C₁₆H₁₂ClNOS₂ [M + H]⁺ calcd. 334.0124, found 334.0135.

3-Benzyl-5-(3-chlorophenyl)-2-thioxothiazolidin-4-one, 6f

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.0/9.0); Colorless oil (142 mg, 86%); ¹H NMR (500 MHz, CDCl₃) δ : 7.40 (d, *J* = 7.0 Hz, 2H), 7.34 - 7.28 (m, 6H), 7.17 (d, *J* = 7.9 Hz, 1H), 5.26 (d, *J* = 14.4 Hz, 1H), 5.21 (s, 1H), 5.16 (d, *J* = 14.1 Hz,

1H); ${}^{13}C{}^{1}H$ NMR (151 MHz, CDCl₃) δ : 199.2, 174.6, 135.8, 135.4, 134.7, 130.7, 129.6, 129.0, 128.8, 128.5, 126.6, 53.8, 48.1.; HRMS (ESI⁺) $m/z C_{16}H_{12}CINOS_2 [M + H]^+$ calcd. 334.0124, found 334.0128.

3-Benzyl-5-(4-nitrophenyl)-2-thioxothiazolidin-4-one, 6g

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.5/8.5); Colorless oil (122 mg, 71%); ¹H NMR (500 MHz, CDCl₃) δ : 8.25 - 8.21 (m, 2H), 7.65 (d, *J* = 7.7 Hz, 1H), 7.59 (t, *J* = 7.9 Hz, 1H), 7.42 (d, *J* = 6.6 Hz, 2H), 7.32 (d, *J* = 6.6 Hz, 3H), 5.38 (s,

1H), 5.28 (d, J = 14.3 Hz, 1H), 5.20 (d, J = 14.3 Hz, 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ : 198.3, 174.25, 148.8, 136.0, 134.5, 134.4, 130.6, 129.0, 128.9, 128.5, 124.3, 123.6, 53.5, 48.3.; HRMS (ESI⁺) $m/z C_{16}H_{12}N_2O_3S_2 [M + H]^+$ calcd. 345.0364, found 345.0383.



Ö 6e

MeO

6d





3-Phenethyl-5-phenyl-2-thioxothiazolidin-4-one, 6h

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.0/9.0); White solid (139 mg, 89%); mp: 108-110 °C; ¹H NMR (500 MHz, CDCl₃) δ : 7.36 - 7.35 (m, 3H), 7.30 - 7.19 (m, 7H), 5.19 (s, 1H), 4.31 - 4.23 (m, 2H), 3.03 - 2.99 (m, 2H); ¹³C{¹H} NMR (126

MHz, CDCl₃) δ: 200.0, 174.9, 137.3, 133.8, 129.4, 129.2, 129.1, 128.8, 128.4, 127.0, 54.4, 46.0, 32.8.; HRMS (ESI⁺) *m/z* C₁₇H₁₅NOS₂ [M + H]⁺ calcd. 314.0668, found 314.0661.

3-Methyl-5-phenyl-2-thioxothiazolidin-4-one, 6i7

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.0/9.0); White solid (100 mg, 90%); mp: 105-107 °C; ¹H NMR (500 MHz, CDCl₃) δ : 7.42 - 7.34 (m, 5H), 5.28 (s, 1H), 3.44 (s, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ : 200.3, 175.0, 133.7, 129.4, 129.3, 128.4, 54.8, 31.8.; HRMS (ESI⁺) *m/z* C₁₀H₉NOS₂ [M + H]⁺ calcd. 224.0199, found 224.0201.

5-Phenyl-3-propyl-2-thioxothiazolidin-4-one, 6j

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.0/9.0); White solid (109 mg, 87%); mp:112-114 °C; ¹H NMR (500 MHz, CDCl₃) δ : 7.39 - 7.31 (m, 5H), 5.23 (s, 1H), 4.00 (t, *J* = 15 Hz, 2H), 1.70 (tq, *J* = 14.6, 7.3 Hz, 2H), 0.93 (t, *J* = 7.4 Hz, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ :

200.2, 175.1, 134.0, 129.4, 129.2, 128.3, 54.4, 46.5, 20.3, 11.2.; HRMS (ESI⁺) *m/z* C₁₂H₁₃NOS₂ [M + H]⁺ calcd. 252.0512, found 252.0506.

3-(2-Hydroxyethyl)-5-phenyl-2-thioxothiazolidin-4-one, 6k

v/v = 3.0/7.0; White solid (103 mg, 82%); mp: 125-127 °C; ¹H NMR (500 MHz, CDCl₃) δ : 7.40 - 7.32 (m, 5H), 5.28 (s, 1H), 4.27 - 4.19 (m, 2H), 3.87 (q, J = 5.6 Hz, 2H), 2.20 (t, J = 5.9 Hz, 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ : 200.9, 175.9,

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane,

133.8, 129.4, 129.3, 128.4, 59.6, 54.5, 46.8.; HRMS (ESI⁺) m/z C₁₁H₁₁NO₂S₂ [M + H]⁺ calcd. 254.0306, found 254.0305.

3-(2,2-Dimethoxyethyl)-5-phenyl-2-thioxothiazolidin-4-one, 6l

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 0.5/9.5); White solid (130 mg, 88%); mp: 120-122 °C; ¹H NMR (500 MHz, CDCl₃) δ : 7.40 - 7.32 (m, 5H), 5.26 (s, 1H), 4.91 (t, *J* = 5.9 Hz, 1H), 4.23 - 4.16 (m, 2H), 3.38 (s, 3H), 3.34 (s, 3H); ¹³C{¹H} NMR (126





HO

6k

6i



MHz, CDCl₃) δ : 200.3, 174.9, 134.2, 129.4, 129.3, 128.4, 99.2, 54.4, 53.9, 53.8, 45.0.; HRMS (ESI⁺) *m/z* C₁₃H₁₅NO₃S₂ [M + H]⁺ calcd. 298.0566, found 298.0575.

3-Allyl-5-phenyl-2-thioxothiazolidin-4-one, 6m

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.5/8.5); Yellow liquid (110 mg, 89%); ¹H NMR (500 MHz, CDCl₃) δ : 7.40 - 7.31 (m, 5H), 5.89 - 5.77 (m, 1H), 5.28 - 5.21 (m, 3H), 4.63 (d, J = 5.6 Hz, 2H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ : 199.5, 174.6,

133.8, 129.45, 129.40, 129.2, 128.3,119.6, 54.4, 46.7.; HRMS (ESI⁺) *m/z* C₁₂H₁₁NOS₂ [M + H]⁺ calcd. 250.0355, found 250.0354.

3-Cyclohexyl-5-phenyl-2-thioxothiazolidin-4-one, 6n

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.0/9.0); White solid (107 mg, 74%); mp: 133-135 °C; ¹H NMR (500 MHz, CDCl₃) δ : 7.41 - 7.29 (m, 5H), 5.05 (s, 1H), 4.93 (tt, J = 12.6, 8.3, 3.6 Hz, 1H), 2.35 - 2.23 (m, 2H), 1.87 - 1.82 (m, 2H), 1.72 - 1.62 (m, 3H),

1.36 (qt, J = 13.1, 3.3 Hz, 2H), 1.20 (ddt, J = 19.9, 13.3, 3.8 Hz, 1H); ¹³C {¹H} NMR (126 MHz, CDCl₃) δ : 201.3, 175.5, 134.6, 129.5, 129.2, 128.3, 58.7, 52.5, 27.8, 27.7, 26.1, 26.0, 25.1.; HRMS (ESI⁺) m/zC₁₅H₁₇NOS₂ [M + H]⁺ calcd. 292.0825, found 292.0830.

5-Phenyl-3-(phenylamino)-2-thioxothiazolidin-4-one, 60

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 2.5/7.5); Red solid (114 mg, 76%); mp: 80-82 °C; ¹H NMR (500 MHz, DMSO-d₆) δ : 9.05 (s, 1H), 7.48 - 7.41 (m, 5H), 7.21 (t, *J* = 7.4 Hz, 2H), 6.83 (t, *J* = 7.3 Hz, 1H), 6.71 (d, *J* = 7.9 Hz, 2H), 6.07 (s,

1H);¹³C{¹H} NMR (126 MHz, DMSO-d₆) δ : 199.4, 173.3, 145.7, 134.9, 129.8, 129.6, 129.5, 129.2, 120.8, 113.0, 51.5.; HRMS (ESI⁺) m/z C₁₅H₁₂N₂OS₂ [M + H]⁺ calcd. 301.0464, found 301.0461.

3,5-Dibenzyl-2-thioxothiazolidin-4-one, 6p

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.0/9.0); Colorless oil (129 mg, 83%); ¹H NMR (600 MHz, CDCl₃) δ : 7.29 - 7.25 (m, 8H), 7.17 - 7.16 (m, 2H), 5.16 - 5.10 (m, 2H), 4.46 (dd, *J* = 9.4, 4.0 Hz, 1H), 3.50 (dd, *J* = 14.1, 4.0 Hz, 1H), 3.12 (dd,

J = 14.1, 9.4 Hz, 1H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ : 200.2, 175.9, 135.6, 134.8, 129.3, 129.0, 128.7, 128.1, 127.8, 52.7, 47.7, 38.3.; HRMS (ESI⁺) m/z C₁₇H₁₅NOS₂ [M + H]⁺ calcd. 314.0668, found 314.0664.



Ö 60



. 6 т

3-Benzvl-2-thioxothiazolidin-4-one, 6a⁸

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.5/8.5; Yellow solid (100 mg, 90%); mp: 84-86 °C; ¹H NMR (600 MHz, CDCl₃) δ : 7.46 (dd, J = 7.9, 1.5 Hz, 2H), 7.35 - 7.29 (m, 3H), 5.20 (s, 2H), 3.97 (s, 2H); ¹³C {¹H} NMR (151 MHz, CDCl₃) δ: 201.1, 173.9, 134.8, 129.1, 128.6, 128.3, 47.7, 35.5.; HRMS

 $(ESI^{+}) m/z C_{10}H_9NOS_2 [M + H]^{+} calcd. 224.0201, found 224.0211.$

3-Ethyl-2-thioxothiazolidin-4-one, 6r⁸

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v =1.5/8.5); Yellow liquid (70 mg, 87%); ¹H NMR (600 MHz, CDCl₃) δ : 4.06 (q, J = 7.1 Hz, 2H), 3.97 (s, 2H), 1.22 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ : 201.1, ő 173.8, 40.0, 35.5, 12.1.; HRMS (ESI⁺) *m/z* C₅H₇NOS₂ [M + H]⁺ calcd. 162.0042, found 162.0048.

3-(2,2-Dimethoxyethyl)-2-thioxothiazolidin-4-one, 6s

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.5/8.5; Yellow liquid (97 mg, 88%); ¹H NMR (600 MHz, CDCl₃) δ ; 4.85 (t, J = 5.7 Hz, 1H), 4.14 (d, J = 5.7 Hz, 2H), 4.01 (s, 2H), 3.37 (s, 6H); ${}^{13}C{}^{1}H$ NMR 6s (151 MHz, CDCl₃) δ : 201.6, 173.7, 99.3, 53.9, 45.0, 35.5.; HRMS (ESI⁺) m/z C₇H₁₁NO₃S₂ [M + H]⁺ calcd. 222.0253, found 222.057.

Methyl 2-(4-oxo-2-thioxothiazolidin-3-yl)acetate, 6t⁹

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.5/8.5; Yellow liquid (90 mg, 90%); ¹H NMR (600 MHz, CDCl₃) δ : 4.73 (s, 2H), 4.09 (s, 2H), 3.77 (s, 3H); ${}^{13}C{}^{1}H{}$ NMR (151 MHz, CDCl₃) δ : 200.6, 173.1, 166.4, 52.9, 44.8, 35.7.

3-Allyl-2-thioxothiazolidin-4-one, 6u⁸

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v =1.5/8.5); Yellow liquid (74 mg, 86%); ¹H NMR (500 MHz, CDCl₃) δ: 5.84 -5.76 (m, 1H), 5.26 (dd, J = 19.9, 13.7 Hz, 2H), 4.61 (d, J = 6.3 Hz, 2H), 4.00 (s, 2H); ${}^{13}C{}^{1}H$ NMR (151 MHz, CDCl₃) δ: 200.8, 173.6, 129.5, 119.7, 46.6, 35.5.; HRMS (ESI⁺) *m/z* C₆H₇NOS₂ [M + H]⁺

calcd. 174.0042, found 174.0047.

3-(Phenylamino)-2-thioxothiazolidin-4-one, 6v

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 2.5/7.5; Red solid (89 mg, 80%); mp: 131-133 °C; ¹H NMR (500 MHz, CDCl₃) δ: 7.26 (t, J = 7.9 Hz, 2H), 7.01 (t, J = 7.4 Hz, 1H), 6.80 (m, 3H), 4.04 (s, 2H);



6r









¹³C{¹H} NMR (126 MHz, CDCl₃) δ: 197.7, 170.3, 144.1, 129.5, 123.3, 115.4 32.7.; HRMS (ESI⁺) m/z $C_9H_8N_2OS_2 [M + H]^+$ calcd. 225.0151, found 225.0149.

11. Unsuccessful examples of primary amines:



12. General procedure for synthesis of compounds, 8

To a stirred solution of CS₂ (0.75 mmol, 1.5 equiv.) in MeOH (3 mL) were added corresponding 2° amines 7 (0.6 mmol, 1.2 equiv.) and α -ester sulfoxonium ylide 1 (0.5 mmol, 1.0 equiv.) at room temperature, and the reaction mixture was stirred for 1.5 h. After completion of reaction as monitored by TLC, the solvent was evaporated under reduce pressure and extracted with EtOAc (3 x 10 mL). The organic extract was dried over anhydrous Na₂SO₄ and removed solvent under reduced pressure. The crude product was purified by column chromatography (silica gel, 100-200 mesh; ethyl acetate/hexane 0.5/9.5) which afforded the desired product 8 in good to excellent yields.

13. Characterization of Compounds, 8

Methyl 2-((dimethylcarbamothioyl)thio)-2-phenylacetate, 8a

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 0.5/9.5; Light yellow solid (117 mg, 87%); mp: 90-92 °C; ¹H NMR (600 MHz, $CDCl_3$) δ : 7.44 (d, J = 7.0 Hz, 2H), 7.36 - 7.33 (m, 3H), 5.76 (s, 1H), 3.76 (s, 3H), 3.51 (s, 3H), 3.36 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ: 194.9, 170.7, 133.7, 129.0, 128.9, 128.8, 59.4, 53.1, 45.3, 41.7.; HRMS (ESI⁺) m/z C₁₂H₁₅NO₂S₂ [M + H]⁺ calcd. 270.0617, found 270.0616.

Methyl 2-((diethylcarbamothioyl)thio)-2-phenylacetate, 8b¹⁰

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 0.5/9.5; Light yellow solid (126 mg, 85%); mp: 93-95 °C; ¹H NMR (600 MHz, CDCl₃) δ : 7.44 (d, J = 7.0 Hz, 2H), 7.35 - 7.33 (m, 3H), 5.79 (s, 1H), 3.99 (dd, J =12.9, 6.1 Hz, 2H), 3.76 (brs, 4H), 3.70 - 3.64 (m, 1H), 1.30 - 1.25 (m, 6H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ: 193.4, 170.8, 133.9, 129.08, 129.04, 128.8, 59.0, 53.1, 49.6, 47.1, 12.7, 11.7.



Ö

8a

Methyl 2-((dibenzylcarbamothioyl)thio)-2-phenylacetate, 8c

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 0.5/9.5; Light yellow liquid (155 mg, 74%); ¹H NMR (500 MHz, CDCl₃) δ : 7.45 (d, J = 7.7 Hz, 2H), 7.34 - 7.31 (brs, 9H), 7.22 - 7.20 (m, 4H), 5.87 (s, 1H), 5.29 (d, J = 14.8 Hz, 1H), 5.21 (d, J = 14.9 Hz, 1H), 4.88 (q,

J = 16.4 Hz, 2H), 3.79 (s, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ : 197.4, 170.5, 135.4, 134.4, 133.5, 129.13, 129.11, 128.9, 128.8, 128.2, 128.1, 128.0, 127.5, 59.8, 55.9, 54.4, 53.2; HRMS (ESI^+) m/z $C_{24}H_{23}NO_2S_2 [M + H]^+$ calcd. 422.1243, found 422.1224.

Methyl 2-phenyl-2-((pyrrolidine-1-carbonothioyl)thio)acetate, 8d¹⁰

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.0/9.0; Light yellow solid (112 mg, 76%); mp: 104-105 °C; ¹H NMR (500 MHz, DMSO-d₆) δ: 7.41 - 7.34 (m, 5H), 5.75 (s, 1H), 3.76 - 3.71 (m, 2H), 3.65 - 3.53 (m, 5H), 2.03 - 1.96 (m, 2H), 1.92 - 1.88 (m, 2H); ¹³C{¹H} NMR (126 MHz, DMSO d_6) δ :188.3, 169.7, 133.9, 129.0, 128.6, 128.5, 57.3, 55.0, 52.8, 50.6, 25.7, 23.7.; HRMS (ESI⁺) $m/z C_{14}H_{17}NO_2S_2 [M + H]^+$ calcd. 296.0774, found 296.0767.

Methyl 2-((morpholine-4-carbonothioyl)thio)-2-phenylacetate, 8e¹⁰

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 2.0/8.0; White solid (146 mg, 94%); mp: 110-112 °C; ¹H NMR (500 MHz, $CDCl_3$ δ : 7.41 (d, J = 8.1 Hz, 2H), 7.38 - 7.31 (m, 3H), 5.80 (s, 1H), 4.25 (brs, 2H), 3.89 (brs, 2H), 3.73 (brs, 7H); ${}^{13}C{}^{1}H$ NMR (126 MHz, CDCl₃) δ : 195.0, 170.4, 133.4, 129.0, 128.9, 128.8, 66.1, 58.7, 53.1, 50.8.

Methyl 2-phenyl-2-((piperidine-1-carbonothioyl)thio)acetate, 8f¹⁰

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 2.0/8.0; White solid (146 mg, 95%); mp: 103-105 °C; ¹H NMR (500 MHz, CDCl₃) δ: 7.44 (d, *J* = 10.3 Hz, 2H), 7.37 - 7.30 (m, 3H), 5.82 (s, 1H), 4.35 (brs, 1H), 4.10 (brs, 1H), 3.90 (brs, 1H), 3.76 (brs, 4H), 1.69 (brs, 6H); ¹³C{¹H} NMR (126 MHz, CDCl₃) & 193.4, 170.8, 133.9, 129.08, 129.04, 128.8, 59.0, 53.1, 52.8, 51.7, 26.1, 25.5, 24.3.

Methyl 2-((piperidine-1-carbonothioyl)thio)-2-(p-tolyl)acetate, 8g

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 2.0/8.0; White solid (145 mg, 90%); mp: 114-116 °C; ¹H NMR (500 MHz, $CDCl_3$) δ : 7.33 (d, J = 7.9 Hz, 2H), 7.15 (d, J = 7.8 Hz, 2H), 5.76 (s, 1H), 4.35 (brs, 1H), 4.09 (brs, 1H), 3.90 (brs, 1H), 3.75 (br, 4H), 2.33 (s, 3H), 1.69 (brs, 6H);

ö 8d









 $^{13}C{}^{1}H{} NMR (126 MHz, CDCl_3) \delta: 193.5, 170.9, 138.7, 130.7, 129.8, 128.9, 58.7, 53.1, 52.71, 51.70, 138.7, 130.7, 129.8, 128.9, 58.7, 53.1, 52.71, 51.70, 138.7, 130.7, 129.8, 128.9, 58.7, 53.1, 52.71, 51.70, 138.7, 130.7, 129.8, 128.9, 58.7, 53.1, 52.71, 51.70, 138.7, 130.7, 129.8, 128.9, 58.7, 53.1, 52.71, 51.70, 138.7, 130.7, 129.8, 128.9, 58.7, 53.1, 52.71, 51.70, 138.7, 130.7, 129.8, 128.9, 58.7, 53.1, 52.71, 51.70, 138.7, 130.7, 129.8, 128.9, 58.7, 53.1, 52.71, 51.70, 138.7, 130.7, 129.8, 128.9, 58.7, 53.1, 52.71, 51.70, 138.7, 130.7, 129.8, 128.9, 58.7, 53.1, 52.71, 51.70, 149.8,$ 26.1, 25.5, 24.2, 21.3.; HRMS (ESI⁺) $m/z C_{16}H_{21}NO_2S_2 [M + H]^+$ calcd. 324.1087, found 324.1085.

Methyl 2-((piperidine-1-carbonothioyl)thio)-2-(o-tolyl)acetate, 8h

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 2.0/8.0; White solid (143 mg, 89%); mp: 115-118 °C; ¹H NMR (600 MHz, $CDCl_3$ δ : 7.33 (d, J = 7.6 Hz, 1H), 7.22 (s, 2H), 7.16 (s, 1H), 6.02 (s, 1H), 4.34 (brs, 1H), 4.14 (brs, 1H), 3.88 (brs, 1H), 3.82 (s, 1H), 3.76 (s, 3H), 2.47 (s, 3H), 1.70 (s, 6H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ: 193.7, 171.1, 137.2, 132.0, 131.0, 128.8, 128.5, 126.5, 56.0, 53.1, 52.9, 51.7, 26.1, 25.4, 24.2, 19.8.; HRMS (ESI⁺) $m/z C_{16}H_{21}NO_2S_2 [M + H]^+$

calcd. 324.1087, found 324.1088.

Methyl 2-((morpholine-4-carbonothioyl)thio)-2-(o-tolyl)acetate, 8i

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 2.0/8.0; White solid (147 mg, 91%); mp: 108-110 °C; ¹H NMR (600 MHz, $CDCl_3$) δ : 7.32 (d, J = 7.6 Hz, 1H), 7.23 (s, 2H), 7.17 (m, 1H), 6.01 (s, 1H), 4.29 (brs, 2H), 3.93 (brs, 2H), 3.76 (s, 7H), 2.47 (s, 3H); ${}^{13}C{}^{1}H{}$ NMR (151 MHz, CDCl₃) δ : 195.6, 170.9, 137.1, 131.6, 131.1, 129.0, 128.5, 126.6, 66.4, 66.1, 55.8, 53.2, 51.1, 50.6, 19.8.; HRMS (ESI⁺) *m/z* C₁₅H₁₉NO₃S₂ [M + H]⁺ calcd. 326.0879, found 326.0877.

Methyl 2-(4-chlorophenyl)-2-((pyrrolidine-1-carbonothioyl)thio)acetate, 8j

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.5/8.5); Light yellow solid (123 mg, 75%); mp: 103-105 ^oC; ¹H NMR (600 MHz, CDCl₃) δ : 7.40 (d, J = 7.8 Hz, 2H), 7.32 (d, J = 7.9 Hz, 2H), 5.89 (s, 1H), 3.93 - 3.85 (m, 2H), 3.76 (s, 3H), 3.71 - 3.67 (m, 1H), 3.60 -3.56 (m, 1H), 2.07 - 2.06 (m, 2H), 1.98 - 1.95 (m, 2H); ¹³C{¹H} NMR (151 MHz,

CDCl₃) δ: 189.8, 170.5, 134.7, 133.1, 130.3, 129.2, 57.5, 55.2, 53.3, 50.7, 26.3, 24.4.; HRMS (ESI⁺) $m/z C_{14}H_{16}CINO_2S_2 [M + H]^+$ calcd. 330.0384, found 330.0375.

Methyl 2-(4-chlorophenyl)-2-((dimethylcarbamothioyl)thio)acetate, 8k

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 0.5/9.5); White solid (133 mg, 88%); mp: 110-113 °C; ¹H NMR (600 MHz, CDCl₃) δ : 7.39 (d, J = 7.7 Hz, 2H), 7.32 (d, J = 7.8 Hz, 2H), 5.78 (s, 1H), 3.75 (s, 3H), 3.51 (s, 3H), 3.36 (s, 3H); ¹³C{¹H} NMR (151 MHz, $CDCl_3$) δ : 194.3, 170.3, 134.8, 132.7, 130.3, 129.2, 58.6, 53.3, 45.4, 41.7.; HRMS (ESI^+) m/z $C_{12}H_{14}CINO_2S_2 [M + H]^+$ calcd. 304.0227, found 304.0224.







0

ö 8j



Methyl 2-(3-chlorophenyl)-2-((dibenzylcarbamothioyl)thio)acetate, 8l Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 0.5/9.5); Light yellow liquid (166 mg, 73%); ¹H NMR (600 MHz, CDCl₃) δ : 7.47 (s, 1H), 7.35 - 7.20 (m, 13H), 5.88 (s, 1H), 5.30 (d, J = 14.9 Hz, 1H), 5.20 (d, J = 15.1 Hz, 1H), 4.92 - 4.84 (m, 2H), 3.79 (s, 3H);

¹³C{¹H} NMR (151 MHz, CDCl₃) δ: 196.7, 170.0, 135.8, 135.2, 134.9, 134.2, 130.3, 129.2, 129.1, 129.0, 128.0, 128.3, 128.1, 128.0, 59.1, 56.1, 54.4, 53.4.; HRMS (ESI⁺) m/z C₂₄H₂₂ClNO₂S₂ [M + H]⁺ calcd. 456.0855, found 456.0842.

Methyl 2-(3-chlorophenyl)-2-((piperidine-1-carbonothioyl)thio)acetate, 8m

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.5/8.5); White solid (147 mg, 86%); mp: 120-122 °C; ¹H NMR (500 MHz, CDCl₃) δ : 7.45 (s, 1H), 7.34 (dd, J = 6.7, 2.2 Hz, 1H), 7.30 - 7.27 (m, 2H), 5.85 (s, 1H), 4.31 (brs, 1H), 4.14 (brs, 1H), 3.87 (brs, 2H), 3.76 (s, 3H), 1.70 (brs, 6H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ : 192.6, 170.3, 136.2, 134.8, 130.1, 129.0, 128.9, 127.2, 58.3, 53.3, 53.0, 51.7, 26.1, 25.4, 24.2.; HRMS (ESI⁺) m/z C₁₅H₁₈ClNO₂S₂ [M + H]⁺ calcd. 344.0540, found 344.0539.

Methyl 2-((dimethylcarbamothioyl)thio)-2-(4-nitrophenyl)acetate, 8n

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 0.5/9.5); White solid (113 mg, 72%); mp: 110-113 °C; ¹H NMR (500 MHz, CDCl₃) δ : 8.35 (d, J = 2.4 Hz, 1H), 8.19 (t, J = 8.9 Hz, 1H), 7.82 (d, J = 7.6 Hz, 1H), 7.54 (t, J = 7.9 Hz, 1H), 6.05 (s, 1H), 3.78 (s, 3H), 3.53

(s, 3H), 3.39 (s, 3H); ${}^{13}C{}^{1}H$ NMR (126 MHz, CDCl₃) δ : 193.4, 169.7, 148.5, 137.2, 135.2, 130.1, 129.8, 124.1, 124.0, 123.6, 58.6, 58.5, 53.5, 45.8, 41.7.; HRMS (ESI⁺) *m/z* C₁₂H₁₄N₂O₄S₂ [M + H]⁺ calcd. 315.0468, found 315.0469.

Methyl 3-phenyl-2-((piperidine-1-carbonothioyl)thio)propanoate, 80

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.5/8.5); White solid (122 mg, 76%); mp: 97-99 °C; ¹H NMR (500 MHz, CDCl₃) δ : 7.41 (d, J = 7.5 Hz, 2H), 7.32 (t, J = 7.3 Hz, 2H), 7.26 (d, J = 5.8 Hz, 1H), 5.54 (dd, J = 10.0, 5.1 Hz, 1H), 4.31 (brs, 1H), 4.20

(brs, 1H), 3.82 (brs, 2H), 3.58 (s, 3H), 3.47 (dd, J = 15.9, 4.8 Hz, 1H), 3.03 (m, 1H), 1.68 (brs, 6H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ : 193.6, 171.1, 139.2, 128.7, 128.4, 127.9, 52.7, 51.8, 51.5, 40.9, 26.1, 25.0, 24.4.; HRMS (ESI⁺) m/z C₁₆H₂₁NO₂S₂ [M + H]⁺ calcd. 324.1087, found 324.1084.



Ö 80

ö 8m



Methyl 2-((pyrrolidine-1-carbonothioyl)thio)acetate, 8p¹¹

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.5/8.5); White solid (86 mg, 79%); mp: 87-89 °C; ¹H NMR (600 MHz, CDCl₃) δ : 4.19 (s, 2H), 3.92 (t, J = 7.0 Hz, 2H), 3.77 (s, 3H), 3.71 (t, J = 6.9 Hz, 2H), 2.10 (p, J = 6.8 Hz, 2H), 1.99 (p, J = 6.8 Hz, 2H); ${}^{13}C{}^{1}H$ NMR (151 MHz,

Methyl 2-((diethylcarbamothioyl)thio)acetate, 8q¹¹

CDCl₃) δ: 190.8, 169.4, 55.5, 52.9, 50.8, 38.4, 26.2, 24.4.

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 0.5/9.5); Light yellow liquid (95 mg, 87%); ¹H NMR (600 MHz, CDCl₃) δ : 4.17 (s, 2H), 4.02 (q, J = 7.0 Hz, 2H), 3.80 - 3.76 (m, 5H), 1.33 (t, J = 7.1 Hz, 3H), 1.27 (t, J = 7.0 Hz, 3H); ${}^{13}C{}^{1}H$ NMR (151 MHz, CDCl₃) δ : 193.8, 169.4, 52.9, 50.1, 47.1, 39.0, 12.7, 11.6.

Methyl 2-((morpholine-4-carbonothioyl)thio)acetate, 8r

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 2.0/8.0; White solid (105 mg, 90%); mp: 95-96 °C; ¹H NMR (600 MHz, CDCl₃) δ: 4.31 (brs, 2H), 4.19 (s, 2H), 3.98 (s, 2H), 3.77 (s,

7H); ${}^{13}C{}^{1}H$ NMR (151 MHz, CDCl₃) δ : 195.6, 169.0, 66.2, 52.9, 51.7, 50.6, 38.7.; HRMS (ESI⁺) m/z $C_{8}H_{13}NO_{3}S_{2}[M + H]^{+}$ calcd. 236.0410, found 236.416.

14. Unsuccessful examples of secondary amines:



15. Synthesis of FE15:

N-(2-Hydroxyphenyl)-3-(4-oxo-2-thioxothiazolidin-3-yl)propanamide, 6w¹²

To a stirred solution of $CS_2 2$ (0.60 mL, 10.0 mmol, 1.50 equiv.) in MeOH (20 mL) were added amine 5w (1.44 g, 8.0 mmol, 1.20 equiv.) and α -ester sulfoxonium ylide 1j (1.0 g, 6.66 mmol, 1.0 equiv.) at room temperature, and the reaction mixture was stirred for 2 h. After completion of reaction as



monitored by TLC, the solvent was evaporated under reduce pressure and extracted with EtOAc (3 x 20 mL). The organic layer was washed with brine, dried over anhydrous Na₂SO₄, concentrated in vacuo

8q

0 ö 8r and then purified by silica gel column chromatography using EtOAc/hexane (4:6, v/v) as eluent to afford the rhodanine derivative, **6w** (1.50 g, 78%) as a yellow solid. mp: 165-168 °C; ¹H NMR (600 MHz, DMSO-d₆) δ : 9.65 (s, 1H), 9.36 (s, 1H), 7.64 (d, J = 7.7 Hz, 1H), 6.94 (t, J = 7.3 Hz, 1H), 6.85 (d, J = 7.6 Hz, 1H), 6.75 (t, J = 7.3 Hz, 1H), 4.25 (s, 2H), 4.15 (t, J = 7.5 Hz, 2H), 2.71 (t, J = 7.5 Hz, 2H); ¹³C {¹H} NMR (151 MHz, DMSO-d₆) δ : 202.9, 174.2, 168.7, 148.3, 125.9, 124.9, 123.0, 118.9, 115.7, 40.5, 35.9, 32.7.

(*Z*)-3-(5-(3-bromobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl)-*N*-(2hydroxyphenyl)propaneide (FE15), 9¹²

To a stirred solution of rhodanine derivative **6w** (1.40 g, 4.70 mmol, 1.0 equiv.) in dry toluene (25 mL) were added NH₄OAc (542 mg, 7.05 mmol, 1.50 equiv.) and 3-Bromobenzaldehyde (1.0 g, 5.64 mmol, 1.20 equiv.) at 100 °C. The reaction mixture was stirred for 4 h at the same temperature. After completion of the reaction, the

reaction was cooled to r.t. and the yellow precipitate was filtered through a Buchner funnel under vacuum, washed with EtOH and hexane to afford the FE15, **9** (1.80 g, 84%) as a yellow solid. mp: 218-220 °C ¹H NMR (600 MHz, DMSO-d₆) δ : 9.66 (s, 1H), 9.40 (s, 1H), 7.83 (s, 1H), 7.77 (s, 1H), 7.67 (d, J = 7.6 Hz, 2H), 7.57 (d, J = 7.5 Hz, 1H), 7.48 (t, J = 7.8 Hz, 1H), 6.93 (t, J = 7.3 Hz, 1H), 6.85 (d, J = 7.7 Hz, 1H), 6.75 (t, J = 7.4 Hz, 1H), 4.32 (t, J = 6.9 Hz, 2H), 2.81 (t, J = 6.9 Hz, 2H); ¹³C {¹H} NMR (151 MHz, DMSO-d₆) δ : 192.8, 168.6, 166.6, 148.1, 135.3, 133.4, 133.3, 131.4, 130.9, 128.6, 125.9, 124.8, 124.1, 122.9, 122.6, 118.9, 115.7, 39.9, 32.9.

16. Characterization of intermediate, IIa

Purified by column chromatography (silica gel 100-200 mesh, ethyl acetate/hexane, v/v = 1.5/8.5); Colorless oil (105 mg, 32%); ¹H NMR (500 MHz, CDCl₃) δ : 8.85 (brs, 1H), 7.40 - 7.31 (m, 14H), 4.82 - 4.72 (m, 3H), 3.67 (s, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ : 190.2, 170.7, 135.6, 133.9, 129.4, 129.0, 128.5, 128.3, 60.1, 53.5, 50.4.; HRMS (ESI⁺) *m/z* C₁₇H₁₇NO₂S₂ [M + H]⁺ calcd. 332.0774, found 332.0775.



FE15,9

17. References:

- (a) S. Thurow, A. A. Fernandes, Y. Quevedo-Acosta, M. F. Oliveira, M. G. Oliveira and I. D. Jurberg, *Org. Lett.*, 2019, **21**, 6909; (b) H. Keipour and T. Ollevier, *Org. Lett.*, 2017, **19**, 5736; (c) C. Matheis, T. Krause, V. Bragoni and L. J. Goossen, *Chem. Eur. J.*, 2016, **22**, 12270.
- (a) V. V. Khade, A. S. Thube, P. K. Warghude and R. G. Bhat, *Tetrahedron Lett.*, 2021, 77, 153258; (b)
 L. S. Munaretto, C. Y. Dos Santos, R. D. Gallo, C. Y. Okada Jr, V. M. Deflon and I. D. Jurberg, *Org.*

let., 2021, **23**, 9292; (c) K. Ramakrishna, A. Jayarani, F. F. Koothradan, C. Sivasankar, *Appl. Organomet. Chem.*, 2020, **34**, 5748.

- 3. Y. Yuan and X. F. Wu, Org. Lett., 2019, 21, 5310.
- 4. T. C. Steuer and C. D. Klein, J. Med. Chem., 2012, 55, 743.
- W. Tejchman, B. Orwat, I. Korona-Głowniak, A. Barbasz, I. Kownacki, G. Latacz and A. Malm, *RSC Adv.*, 2019, 9, 39367.
- 6. F. Nasiri, A. Zolali and Z. J. Azimian, Sulphur Chem., 2014, 35, 62.
- 7. J. Jaźwiński and O. J. Staszewska-Krajewska, Mol. Struct., 2002, 602, 269.
- 8. C. Nitsche and C. D. Klein, Tetrahedron Lett., 2012, 53, 5197.
- B. Hemavathi, V. Jayadev, P. C. Ramamurthy, R. K. Pai, K. N. Narayanan, T. N. Ahipa and R. G. Balakrishna, *New J. Chem.*, 2019, 43, 15673.
- 10. Y. Lv, R. Liu, H. Ding, W. Wei, X. Zhao and L. He, Org. Chem. Front., 2022, 9, 3486.
- 11. N. Azizi, F. Aryanasab, L. Tourkian and M. R. Saidi, Synthetic Comm., 2022, 41, 94.
- 12. G. Maga, F. Falchi, M. Radi, L. Botta, G. Casaluce, M. Bernardini and M. Botta, *Chem. Med. Chem.*, 2011, 6, 1371.

 1H NMR (600 MHz, DMSO-d6) and $^{13}C\{^1H\}$ NMR (151 MHz, DMSO-d6), 4a



 1H NMR (500 MHz, DMSO-d6) and $^{13}C\{^1H\}$ NMR (126 MHz, DMSO-d6), 4b



 1H NMR (500 MHz, DMSO-d6) and $^{13}C\{^1H\}$ NMR (126 MHz, DMSO-d6), 4c



 1H NMR (500 MHz, DMSO-d6) and $^{13}C\{^1H\}$ NMR (126 MHz, DMSO-d6), 4d



 1H NMR (500 MHz, DMSO-d6) and $^{13}C\{^1H\}$ NMR (126 MHz, DMSO-d6), 4e



 1H NMR (500 MHz, DMSO-d6) and $^{13}C\{^1H\}$ NMR (126 MHz, DMSO-d6), 4f



 1H NMR (500 MHz, DMSO-d6) and $^{13}C\{^1H\}$ NMR (126 MHz, DMSO-d6), 4g



 1H NMR (500 MHz, DMSO-d6) and $^{13}C\{^1H\}$ NMR (126 MHz, DMSO-d6), 4i



¹H NMR (600 MHz, DMSO-d6) and ¹³C{¹H} NMR (126 MHz, DMSO-d6), 4j



^1H NMR (500 MHz, CDCl₃) and $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl₃), 6a



S28

 ^1H NMR (500 MHz, CDCl₃) and $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl₃), **6b**



^1H NMR (500 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3), 6c



 1H NMR (500 MHz, CDCl₃) and $^{13}C\{^1H\}$ NMR (126 MHz, CDCl₃), 6d



 ^1H NMR (500 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3), 6e



^1H NMR (500 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3), 6f







S34

 ^1H NMR (500 MHz, CDCl₃) and $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl₃), **6h**



 ^1H NMR (500 MHz, CDCl₃) and $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl₃), 6i







 ^1H NMR (500 MHz, CDCl₃) and $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl₃), **6k**



 ^1H NMR (500 MHz, CDCl₃) and $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl₃), **61**

 1 H NMR (500 MHz, CDCl₃) and 13 C{ 1 H} NMR (126 MHz, CDCl₃), 6m

S40

 ^1H NMR (500 MHz, CDCl₃) and $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl₃), **6n**

 1H NMR (500 MHz, DMSO-d6) and $^{13}C\{^1H\}$ NMR (126 MHz, DMSO-d6), 60

 ^1H NMR (600 MHz, CDCl₃) and $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl₃), **6p**

S43

^1H NMR (600 MHz, CDCl₃) and $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl₃), 6q

 ^1H NMR (600 MHz, CDCl₃) and $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl₃), 6r

 ^1H NMR (600 MHz, CDCl₃) and $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl₃), 6s

 ^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3), 6t

S47

 ^1H NMR (500 MHz, CDCl₃) and $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl₃), **6u**

 ^1H NMR (500 MHz, CDCl₃) and $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl₃), 6v

 ^1H NMR (600 MHz, CDCl₃) and $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl₃), 8a

S50

 ^1H NMR (600 MHz, CDCl₃) and $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl₃), **8b**

 1H NMR (500 MHz, CDCl_3) and $^{13}C\{^1H\}$ NMR (126 MHz, CDCl_3), 8c

¹H NMR (500 MHz, DMSO-d6) and ¹³C{¹H} NMR (126 MHz, DMSO-d6), **8d**

 ^1H NMR (500 MHz, CDCl₃) and $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl₃), 8e

S54

 ^1H NMR (500 MHz, CDCl₃) and $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl₃), **8f**

1H NMR (500 MHz, CDCl_3) and $^{13}C\{^1H\}$ NMR (126 MHz, CDCl_3), 8g

¹H NMR (600 MHz, CDCl₃) and ¹³C $\{^{1}H\}$ NMR (151 MHz, CDCl₃), 8h

 ^1H NMR (600 MHz, CDCl₃) and $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl₃), 8i

 1 H NMR (600 MHz, CDCl₃) and 13 C{ 1 H} NMR (151 MHz, CDCl₃), 8j

S59

 ^1H NMR (600 MHz, CDCl₃) and $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl₃), 8k

 ^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3), 81

 1H NMR (500 MHz, CDCl₃) and $^{13}C\{^1H\}$ NMR (126 MHz, CDCl₃), **8m**

 ^1H NMR (500 MHz, CDCl₃) and $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl₃), **8n**

S63

 ^1H NMR (500 MHz, CDCl₃) and $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl₃), 80

¹H NMR (600 MHz, $CDCl_3$) and ¹³C{¹H} NMR (151 MHz, $CDCl_3$), **8p**

¹H NMR (600 MHz, $CDCl_3$) and ¹³C{¹H} NMR (151 MHz, $CDCl_3$), 8q

 ^1H NMR (600 MHz, CDCl₃) and $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl₃), 8r

 1H NMR (600 MHz, DMSO-d6) and $^{13}C\{^1H\}$ NMR (151 MHz, DMSO-d6), $\mathbf{6w}$

 1H NMR (600 MHz, DMSO-d6) and $^{13}C\{^1H\}$ NMR (151 MHz, DMSO-d6), $\boldsymbol{9}$

 1 H NMR (500 MHz, CDCl₃) and 13 C{ 1 H} NMR (126 MHz, CDCl₃), IIa

